Dexmedetomidine Versus Nitroglycerin on Surgical Field Quality and Drug Cost in Functional Endoscopic Sinus Surgeries
Impact of Dexmedetomidine Versus Nitroglycerin on Surgical Field Quality and Drug Cost in Functional Endoscopic Sinus Surgeries
Sinus surgery is one of the most prevalent ear, nose, and throat (ENT) surgeries, which is mainly carried out nowadays through functional endoscopic sinus surgery (FESS) and leads to significant improvement in the clinical symptoms of patients with rhinosinusitis. It is necessary to maintain safe conditions for this surgery, and the major problem reported during FESS under general anesthesia (GA) is impaired visibility due to excessive amount of bleeding. This is particularly important for the successful surgery of the ethmoid and sphenoid sinuses because even minimum amount of bleeding might seriously impair the successful completion of the surgery, increase the operational risk, and increase surgery time which are major concerns for both anesthesiologist and ENT specialist.
Controlled hypotension is the commonly used technique to limit blood loss and improve visualization in the surgical field during FESS, various techniques have been adopted to achieve controlled hypotension, one of them is the use of pharmacological drugs in the form of volatile anesthetics, direct-acting vasodilators, autonomic ganglion-blockers, and α-adrenergic receptor blockers.
Alpha-2 (α-2) receptors are found in the peripheral and central nervous systems, platelets and many other organs including the liver, pancreas, kidney, and eye. Stimulation of the receptors in the brain and spinal cord inhibits neuronal firing causing hypotension, bradycardia, sedation, and analgesia. Alpha-2 (α-2) agonist drugs have sympatholytic, sedative, anesthetic, and analgesic sparing effects, as well as vasoconstrictive effects and thereby reduce intraoperative bleeding. Also, the use of α-2 agonists in the perioperative period has been associated with reduced anesthetic requirements, decreased heart rate and blood pressure.
Dexmedetomidine is a highly selective α-2 adrenergic receptor agonist (selectivity ratio for α2: α1 is 1600:1). The sympatholytic effect of dexmedetomidine made it attractive to be used as a hypotensive drug during surgery because of decreasing heart rate (HR) and cardiac output (CO) without decreasing stroke volume unless the plasma concentrates reaches above 5.1 μg/mL. The cardiovascular effects of dexmedetomidine begin with initial hypertension following the administration of a loading dose, due to the activation of α 2B receptors located on vascular smooth muscle, with subsequent hypotension and bradycardia due to centrally mediated decrease in sympathetic tone. Dexmedetomidine also has sedative, amnesic, anxiolytic, hypnotic, and analgesic effects with minimal changes in respiratory variables. Furthermore, it reduces postoperative nausea, vomiting, and shivering. It also reduces delirium in patients after cardiac surgery.
Nitroglycerin is a directly acting vasodilator drug frequently used to produce controlled hypotension because it is easily titratable and having very rapid onset as well as rapid offset of action. However, the disadvantages of nitroglycerin are reflex tachycardia and venous congestion which leads to increased blood loss.
Aim of the work was improving surgical field quality and drug cost in patients undergoing Functional Endoscopic Sinus Surgeries by comparing between dexmedetomidine and nitroglycerin.
調査の概要
状態
詳細な説明
This study had been carried out in Anesthesia, Intensive Care and Pain management Department - Faculty of Medicine - Zagazig University Hospitals.
Sample size:
Assuming the average category scale was 73.33% vs 36.67% in group D vs group N, so the sample was 66 adult male and female undergoing FESS , 33 cases in each group (dexmedetomidine and nitroglycerin) using open EPI info with CI 95%, Power of test 80%.
Withdrawal criteria:
The patient has the right to withdraw from the study at any time without any negative consequences or harm on his/her medical treatment plan.
Randomization:
All Patients were randomly allocated into 2 equal groups. Patients were randomized using computer generated randomization table in a 1:1 ratio and allocated either in dexmedetomidine group (group D) or nitroglycerin group (group N).
Randomization assignments were kept in sealed envelopes until the day of surgery, and then they opened by the research anesthesiologist immediately prior to the operation.
Process:
- All participating patients were interviewed preoperatively during their preoperative preparation. The goal and endpoints of the study were discussed. Understanding of the technique was reviewed and emphasized.
- History was taken, clinical examination was done, and informed written consent was obtained.
- Fasting before the operation (8 hours for solid meal and 2 hours for clear fluids).
- IV line was inserted; midazolam (0.02-0.05 mg/kg) was given as a premedication, started IV fluids as ringer lactate (8-10 ml/kg).
- 10 minutes before induction of anesthesia, full monitoring including noninvasive arterial blood pressure, electrocardiogram, pulse oximetry, and capnogram (after induction of anesthesia) were applied and basal readings were recorded.
- Preoxygenation with 100% oxygen for 3 minutes before induction.
Group (D):
Started infusion of a loading dose of dexmedetomidine 1 μg /kg over 10 minutes before induction of anesthesia.
Induction:
• Fentanyl IV (2 μg/kg), Propofol IV (2 mg/kg), and Rocuronium IV (1mg/kg).
Maintenance:
- Maintenance of anesthesia was done with isoflurane inhalation at 1-2 minimum alveolar concentration (MAC) and incremental doses of rocuronium 0.5mg/kg every 45 minutes.
- IV infusion of dexmedetomidine 0.3-0.7 µg/kg/h. Group (N)
Induction:
• Fentanyl IV (2 μg/kg), Propofol IV (2 mg/kg), and Rocuronium IV (1 mg/kg).
Maintenance:
- Maintenance of anesthesia was done with isoflurane inhalation at 1-2 (MAC) and incremental doses of rocuronium 0.5 mg/kg every 45 minutes.
- IV infusion of nitroglycerin at a dose of 0.5-2 µg/kg/min. Both drugs (dexmedetomidine and nitroglycerin) were titrated till mean arterial pressure (MAP) 60-70 mmHg, or a MAP below 30% of baseline.
Operations for both groups were carried out by the same surgical team. All the patients, surgeons, and the attending anesthetist who was assigned to record the patients' parameters were blinded to the infused drugs. The randomization envelopes, the syringe pumps, and their code labels were prepared by an anesthetist independent in the study.
Recovery period:
Patients were recovered with neostigmine (0.05-0.08 mg/kg) and atropine, the standard analgesia (paracetamol) was started at a dose of (15 mg/kg) then patients were transferred to the post anesthesia care unit (PACU) for observation.
Measurements:
• The visibility of the surgical field was assessed by surgeon using Fromme and Boezaart scoring system:-
Fromme and Boezaart scoring system:
Grade Assessment 0 No bleeding (cadaveric conditions) I Slight bleeding, no suctioning required II Slight bleeding, occasional suctioning required III Slight bleeding, frequent suctioning required; bleeding threatens surgical field a few seconds after suction is removed IV Moderate bleeding, frequent suctioning required, and bleeding threatens surgical field directly after suction is removed V Severe bleeding, constant suctioning required; bleeding appears faster than can be removed by suction; surgical field severely threatened and surgery usually not possible Heart rate and MAP basal readings were recorded then at 15 minutes time interval intraoperative.
Emergence time defined as the interval between discontinuation of the anesthetics to response of eye opening to the verbal command.
Recovery time defined as the time from end of surgery (i.e., final wound covered) until the patient left for the hospital ward were recorded.
The postoperative sedation was assessed with Ramsay Sedation Score Observation for any side effects or complications such as nausea, vomiting, shivering, dry mouth, bradycardia, tachycardia, and hypotension.
The cost of both drugs was recorded.
Data collection:
- Patient characteristics: age, sex, BMI, and physical status of patients included in the study.
- MAP, heart rate and assessment score of surgical field intraoperative.
- Emergence and recovery time.
- Sedation score.
- Drug cost.
- Side effects or complications.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Sharqia Province
-
Zagazig、Sharqia Province、エジプト、44111
- Zagazig University
-
-
参加基準
適格基準
就学可能な年齢
- 大人
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Physical status: American Society of Anesthesiologists (ASA) I & II.
- Body Mass Index (BMI): 18.5-30 kg/m2.
- Type of operation: elective bilateral FESS.
- Type of anesthesia: general anesthesia.
Exclusion Criteria:
- Patients with known history of allergy to study drugs.
- Anticipated difficult intubation.
- Advanced hepatic, renal or cardiovascular diseases.
- Central nervous system disorder, metabolic disease, and electrolyte imbalance.
- Coagulopathies or taking drugs affecting coagulation.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:Group D
dexmedetomidine as controlled hypotensive drug
|
Started infusion of a loading dose of dexmedetomidine 1 μg /kg over 10 minutes before induction of anesthesia. Induction: Fentanyl IV (2 μg/kg), Propofol IV (2 mg/kg), and Rocuronium IV (1mg/kg). Maintenance: Maintenance of anesthesia was done with isoflurane inhalation at 1-2 minimum alveolar concentration (MAC) and incremental doses of rocuronium 0.5mg/kg every 45 minutes. IV infusion of dexmedetomidine 0.3-0.7 µg/kg/h. Dexmedetomidine was titrated till mean arterial pressure (MAP) 60-70 mmHg, or a MAP below 30% of baseline. |
|
アクティブコンパレータ:Group N
Nitroglycerin as controlled hypotensive drug
|
Induction: • Fentanyl IV (2 μg/kg), Propofol IV (2 mg/kg), and Rocuronium IV (1 mg/kg). Maintenance:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
The quality of the surgical field
時間枠:perioperative
|
The visibility of the surgical field was assessed by surgeon using Fromme and Boezaart scoring system: 0 No bleeding (cadaveric conditions) I Slight bleeding, no suctioning required II Slight bleeding, occasional suctioning required III Slight bleeding, frequent suctioning required; bleeding threatens surgical field a few seconds after suction is removed IV Moderate bleeding, frequent suctioning required, and bleeding threatens surgical field directly after suction is removed V Severe bleeding, constant suctioning required; bleeding appears faster than can be removed by suction; surgical field severely threatened and surgery usually not possible |
perioperative
|
|
Drug cost
時間枠:perioperative
|
estimate and compare the drug cost in both groups by Egyptian pounds
|
perioperative
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Emergence time
時間枠:perioperative
|
the interval between discontinuation of the anesthetics to response of eye opening to the verbal command
|
perioperative
|
|
Mean arterial pressure
時間枠:basal, 15 minutes, 30 minutes, 45 minutes, 60 minutes, 75 minutes, 90 minutes, 105 minutes, 120 minutes
|
MAP basal readings were recorded then at 15 minutes time interval intraoperative till the end of the operation
|
basal, 15 minutes, 30 minutes, 45 minutes, 60 minutes, 75 minutes, 90 minutes, 105 minutes, 120 minutes
|
|
Heart rate
時間枠:basal, 15 minutes, 30 minutes, 45 minutes, 60 minutes, 75 minutes, 90 minutes, 105 minutes , 120 minutes
|
Heart rate basal readings were recorded then at 15 minutes time interval intraoperative till the end of the operation
|
basal, 15 minutes, 30 minutes, 45 minutes, 60 minutes, 75 minutes, 90 minutes, 105 minutes , 120 minutes
|
|
Recovery time
時間枠:perioperative
|
the time from end of surgery (i.e., final wound covered) until the patient left for the hospital ward
|
perioperative
|
|
Complications
時間枠:perioperative
|
Observation for any side effects or complications such as nausea, vomiting, shivering, dry mouth, bradycardia, tachycardia, and hypotension.
|
perioperative
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- ZU-IRB #9667
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。